U.S. FDA approves ChemoCentryx drug to treat rare autoimmune disease By Reuters
[ad_1]
© Reuters. FILEPHOTO: This sign can be seen at White Oak headquarters of Food and Drug Administration in Maryland on August 29, 2020. REUTERS/Andrew Kelly(Reuters) – The U.S. Food and Drug Administration approved ChemoCentryx Inc’s leading drug candidate Avacopan for the treatment of a rare and fatal autoimmune disorder.
Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]